Amphotericin B Intravenous should be administered primarily to patients with progressive, potentially fatal infections. This potent drug should not be used to treat the common non-invasive fungal infections such as oral thrush, vaginal candidiasis and oesophageal candidiasis in patients with normal neutrophil counts. Amphotericin B Intravenous is specifically intended to treat potentially life-threatening fungal infections: cryptococcosis (torulosis); North American blastomycosis; the disseminated forms of moniliasis (candidiasis), coccidioidomycosis and histoplasmosis; mucormycosis (phycomycosis) caused by susceptible species of the genera Mucor, Rhizopus, Absidia, Entomophthora, and Basidiobolus; sporotrichosis (Sporothrix schenckii); aspergillosis (Aspergillus fumigatus). Amphotericin B may be helpful in the treatment of American mucocutaneous leishmaniasis, but is not the drug of choice in primary therapy.
50 mg powder for sterile concentrate (IV)